COLORADO SPRINGS, Colo., Jun 29, 2011 (BUSINESS WIRE) -- Cannabis
Science Inc. (nasd otcbb:CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to
announce that it has been contacted by Lynnice Wedewer, Ph.D. who is a 34 year multiple cancer patient survivor who has been
cured of 7 of her 8 cancers in a major part because of medical cannabis. Dr. Wedewer wishes to share her story through Cannabis
Science and help our case and education towards general acceptance of medical cannabis as a natural and viable treatment for
In 1979, Iowa passed a medical marijuana law which
impacted five children suffering from cancer and who were placed into a cancer treatment program using medical cannabis under
the supervision of the University of Iowa. Dr. Wedewer was one of those children and only 1 1/2 years ago did the law in Iowa
finally change to allow these patients to finally speak out about their treatment and success stories in battling cancer with
The Company is excited to feature
Dr. Lynnice Wedewer's cancer success story and testimonial in its upcoming documentary, along with other cancer survivors
who were cured through the use of medical cannabis.
Wedewer runs a website www.lynnicewedewer.com where she provides her testimony, speeches, educational material, marijuana
facts, interviews and documentaries, and other informational links regarding marijuana.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "These are exciting times to be
part of a burgeoning medical marijuana movement and shedding light on patients who are telling their stories and opening up
medical files to demonstrate the cancer curing power of medical cannabis. We are enthusiastic and hopefully that Dr. Lynnice
Wedewer's testimonial and cancer success along with other patient success stories, including profound medical evidence,
will help to educate and finally open up the eyes of federal regulators to decriminalize medical cannabis; so more people's
lives can be saved by this natural herbal remedy and stop killing people with man-made pharmaceuticals."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The
Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies
to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease,
as well as for general health maintenance.
Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors
that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science Inc.